Targeting the COPD exacerbation

被引:20
作者
Decrarner, Marc [1 ]
Nici, Linda [3 ]
Nardini, Stefano [4 ]
Reardon, Jane [5 ]
Rochester, Carolyn L. [6 ,7 ]
Sanguinetti, Claudio M. [8 ]
Troosters, Thierry [2 ]
机构
[1] Katholieke Univ Leuven Hosp, Div Resp, Louvain, Belgium
[2] Katholieke Univ Leuven, FaBeR, Louvain, Belgium
[3] Vet Adm Med Ctr, Dept Pulm & Crit Care, Providence, RI 02908 USA
[4] Carlo Forlanini Gen Hosp, Div Pulm, Vittorio Veneto, TV, Italy
[5] Hartford Hosp, Dept Med, Hartford, CT 06115 USA
[6] Yale Univ, Sch Med, Sect Pulm & Crit Care, New Haven, CT USA
[7] VA Connecticut Healthcare Syst, New Haven, CT USA
[8] San Filippo Neri Gen Hosp, Div Pulm, Rome, Italy
关键词
COPD; exacerbation; pharmacotherapy; rehabilitation; self-management; systematic consequences and prevention strategies;
D O I
10.1016/S0954-6111(08)70003-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Exacerbations of COPD have a profound detrimental effect on the patient and impose a significant burden on healthcare resource utilization. Prevention and treatment of exacerbations are major objectives of the clinical management of COPD. For this approach to be successful, clinicians must combine both pharmacologic approaches and non-pharmacologic strategies aimed at improving the patient's disease management. Non-pharmacologic approaches include those that can be incorporated into the office setting as well as intervention strategies that are integrated into the lifelong management of COPD. These strategies include developing a partnership with the patient and their social supports, encouraging and facilitating smoking cessation, immunizations, proper use of supplemental oxygen, and most importantly, giving the patient the toots to manage their illness appropriately. Moreover there is clear evidence of an irrevocable decline in pulmonary function after each exacerbation, usually resulting in reduced physical activity and impaired skeletal muscle function. Not surprisingly, pulmonary rehabilitation after such events has been shown to prevent relapse, improve survival and enhance patients' overall function after acute exacerbations. It is now accepted that during an exacerbation there is an increased inflammation both in the lung and in the systemic circulation that can affect many organs and systems, causing serious complications. Several classes of pharmacological agents are currently available which have varying efficacy with regard to preventing exacerbations. However, further knowledge is needed regarding the varying clinical phenotypes of COPD and the mechanisms by which infections and other environmental agents trigger exacerbations, so that ultimately, pharmacologic therapy can be better targeted to provide specific patient benefits. (C) 2008 Elsevier Ltd. ALL rights reserved.
引用
收藏
页码:S3 / S15
页数:13
相关论文
共 95 条
[11]   Inhaled tiotropium for stable chronic obstructive pulmonary disease - art. no. CD002876.pub2 [J].
Barr, RG ;
Bourbeau, J ;
Camargo, CA ;
Ram, FSF .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02)
[12]   Reduction of hospital utilization in patients with chronic obstructive pulmonary disease -: A disease-specific self-management intervention [J].
Bourbeau, J ;
Julien, M ;
Maltais, F ;
Rouleau, M ;
Beaupré, A ;
Bégin, R ;
Renzi, P ;
Nault, D ;
Borycki, E ;
Schwartzmann, K ;
Singh, R ;
Collet, JP .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :585-591
[13]   Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease [J].
Bourbeau, J ;
Rouleau, MY ;
Boucher, S .
THORAX, 1998, 53 (06) :477-482
[14]   Economic benefits of self-management education in COPD [J].
Bourbeau, Jean ;
Collet, Jean-Paul ;
Schwartzman, Kevin ;
Ducruet, Thierry ;
Nault, Diane ;
Bradley, Carole .
CHEST, 2006, 130 (06) :1704-1711
[15]   Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [J].
Brusasco, V ;
Hodder, R ;
Miravitlles, M ;
Korducki, L ;
Towse, L ;
Kesten, S .
THORAX, 2003, 58 (05) :399-404
[16]  
BUIST AS, 1976, AM REV RESPIR DIS, V114, P115
[17]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[18]   Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].
Calverley, P ;
Pauwels, R ;
Vestbo, J ;
Jones, P ;
Pride, N ;
Gulsvik, A ;
Anderson, J ;
Maden, C .
LANCET, 2003, 361 (9356) :449-456
[19]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[20]   Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease [J].
Calverley, PM ;
Boonsawat, W ;
Cseke, Z ;
Zhong, N ;
Peterson, S ;
Olsson, H .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (06) :912-919